在早期研究中，巨大的不可溶的Aβ斑块被认为是引发患者症状的头号元凶。科学家们普遍认为，这些斑块的形成是AD的核心病理特征，也是导致认知功能障碍的主要原因。因此，大量的研究资源和精力被投入到针对Aβ斑块的治疗策略中，希望能够通过清除这些斑块来改善患者的 ...

Aβ的“前身”是正常存在于神经元中的淀粉样前体蛋白（APP），在某些情况下被蛋白酶错误切割而产生。在AD患者的大脑中，Aβ的生成源源不断地 ...

This has been facilitated by the generation of an antibody to synthetic Aβ oligomers that specifically identifies a common structure that is present in several different amyloid-prone synthetic ...

Notably, microglia spatially associated with amyloid plaques exhibited increased expression of TREM2 and ApoE compared to such cells in non-immunized controls, regardless of whether the treatment was ...

Fukumoto, 2002 Formulation: 50 tests: This kit stains Aβ40 or Aβ42 in tissue section by the monoclonal antibodies that detects the portion of C-terminal of Aβ.

Real-time HS-AFM observation of Aβ fibril growth and the 4396C antibody binding at the fibril end Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to ...

Leqembi is a Aβ monoclonal antibody that preferentially binds to toxic protofibrils (soluble Aβ aggregates), in addition to targeting and reducing Aβ plaques (insoluble Aβ aggregates).

Recent clinical trials demonstrating a slowing of cognitive and functional decline in individuals with AD who are treated with anti-Aβ antibodies reinforce the important role of Aβ in the ...

Background High-profile Phase 3 clinical trials of bapineuzumab and solanezumab, antibodies targeted at amyloid-beta (Aβ) removal, have failed to meet their primary endpoints. Neither drug ...